TSXV: ATE   CAD ${{ stocks['ATE.V'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATE.V']) }} ET
OTCQB: ATBPF   USD ${{ stocks['ATBPF'].LastPrice }}
Last updated: {{ getStockDate(stocks['ATBPF']) }} ET
CAD ${{ getMCap(stocks['ATE.V']) }}M
MARKET CAP
CAD ${{ stocks['ATE.V'].YearHigh }}/${{ stocks['ATE.V'].YearLow }}
52-WEEK HIGH/LOW
{{ stocks['ATE.V'].AverageDailyVolume3Month }}
AVG. DAILY TRADING VOLUME
18%
INSIDER OWNERSHIP

Investor Presentation

Learn how Antibe is aiming to change the game in pain and inflammation medicine. Delve into our market opportunity, drug pipeline and the science that underlies our drug platform.

Last updated: June 2020

ANALYST COVERAGE

FIRM                                                                              ANALYST

Echelon Wealth Partners                                      Douglas Loe, PhD, MBA
Paradigm Capital                                                     Scott McAuley, PhD

The opinions, forecasts or estimates of these analysts do not represent those of Antibe Therapeutics or its directors.

Attention

This is an external link. Click “OK” to continue.

CANCEL OK